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SGLT2 inhibition modulates NLRP3 inflammasome
activity via ketones and insulin in diabetes with
cardiovascular disease
So Ra Kim 1,2,3,14, Sang-Guk Lee 4,14, Soo Hyun Kim1, Jin Hee Kim 1,5, Eunhye Choi4, Wonhee Cho6,
John Hoon Rim5,7, Inhwa Hwang5,8, Chan Joo Lee9, Minyoung Lee1, Chang-Myung Oh10, Justin Y. Jeon6,
Heon Yung Gee 5,7, Jeong-Ho Kim 4, Byung-Wan Lee 1,2,11, Eun Seok Kang1,2,5,11, Bong-Soo Cha1,2,5,11,
Myung-Shik Lee 1,12, Je-Wook Yu5,8, Jin Won Cho13, Jung-Sun Kim 9✉ & Yong-ho Lee 1,2,5,11,13✉
Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce cardiovascular events in humans
with type 2 diabetes (T2D); however, the underlying mechanism remains unclear. Activation
of the NLR family, pyrin domain-containing 3 (NLRP3) inflammasome and subsequent
interleukin (IL)-1β release induces atherosclerosis and heart failure. Here we show the effect
of SGLT2 inhibitor empagliflozin on NLRP3 inflammasome activity. Patients with T2D and
high cardiovascular risk receive SGLT2 inhibitor or sulfonylurea for 30 days, with NLRP3
inflammasome activation analyzed in macrophages. While the SGLT2 inhibitor’s glucose-
lowering capacity is similar to sulfonylurea, it shows a greater reduction in IL-1β secretion
compared to sulfonylurea accompanied by increased serum β-hydroxybutyrate (BHB) and
decreased serum insulin. Ex vivo experiments with macrophages verify the inhibitory effects
of high BHB and low insulin levels on NLRP3 inflammasome activation. In conclusion, SGLT2
inhibitor attenuates NLRP3 inflammasome activation, which might help to explain its cardi-
oprotective effects.
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Cardiovascular disease (CVD) is a major cause of morbidityand mortality in patients with type 2 diabetes (T2D), witha two- to fourfold increase in incidence compared with
patients without diabetes1. Diabetes produces an abnormal
metabolic state, including chronic hyperglycemia, dyslipidemia,
insulin resistance, and inflammation, which can lead to the
development of atherosclerosis, a pathologic process implicated in
symptomatic CVD events. A large, multiprotein complex oligo-
merized in the cytoplasm of innate immune cells, known as the
NLR family, pyrin domain-containing 3 (NLRP3) inflammasome,
is stimulated to secrete pathogenic inflammatory cytokines, spe-
cifically interleukin-1β (IL-1β)2. This is involved in the molecular
etiology of numerous chronic inflammatory diseases, including
diabetes, non-alcoholic steatohepatitis, gout, atherosclerosis, and
heart failure2–7.
Sodium–glucose cotransporter 2 (SGLT2) inhibitors lower
serum glucose by increasing urinary glucose excretion8. The
recently published EMPA-REG OUTCOME study demonstrated
that, in patients with T2D and high CVD risk, empagliflozin
reduced adverse cardiac events by 14%, which resulted in a 38%
reduction in cardiovascular (CV) mortality9. It is the first anti-
diabetic agent that reduced CV events beyond glycemic control.
Subsequently, the CANVAS Program also achieved comparable
effects with another SGLT2 inhibitor10. The unique action of
SGLT2 inhibitors corrects several metabolic and hemodynamic
abnormalities that are risk factors for CVD, by decreasing serum
glucose, body weight, and blood pressure and by increasing
diuresis8. However, other underlying mechanisms to explain the
cardioprotective effects of SGLT2 inhibitors are as yet unclear.
Based on their pharmacologic profile, SGLT2 inhibitors cause
mild increases in serum ketone bodies, i.e., β-hydroxybutyrate
(BHB)8. BHB is a convenient carrier of energy from adipocytes to
peripheral tissues, particularly in brain, heart, and skeletal mus-
cles during prolonged fasting or exercise11. Beyond acting as a
metabolite, BHB has important cellular signaling roles. Youm
et al. revealed that BHB suppresses activation of the NLRP3
inflammasome and reduces IL-1β production in macrophages
and mice12. However, there is no report of whether increased
serum BHB concentration inhibits NLRP3 inflammasome acti-
vation in humans. A recent study demonstrated that fasting and
refeeding can differentially regulate NLRP3 inflammasome acti-
vation in human peripheral blood mononuclear cells (PBMCs)13.
This indicates that the dynamic regulation of NLRP3 inflamma-
some activation can be assessed using human PBMCs.
On the basis of the pathogenic effect of the NLRP3 inflam-
masome on CVD and the therapeutic role of BHB on its inhi-
bition, the present study demonstrates that the SGLT2 inhibitor
blocks NLRP3 inflammasome activation by raising circulating
levels of BHB in patients with T2D at high CV risk, which could
explain their cardioprotective effects. To exclude glucose-lowering
effects on inhibition of NLRP3 inflammasome activation, we used
an active comparator, namely sulfonylurea instead of placebo.
Results
Baseline characteristics of study participants. Among
88 screened participants, 71 met the inclusion criteria and were
randomly assigned to treatment with empagliflozin (SGLT2
inhibitor) or glimepiride (sulfonylurea). Ten participants with-
drew prematurely from the trial, which led to 61 participants
completing the study (empagliflozin, 29; and glimepiride, 32)
(Fig. 1).
Baseline characteristics of the study participants are summar-
ized in Table 1. Participants were matched for demographic and
biochemical variables. As metformin is first-line therapy, most
participants in both groups were taking it and continued on the
same dosage during the study period. Adverse events related to
study drugs were uncommon, although discontinuation of study
drug occurred once in each group (Supplementary Table 1).
Effects of SGLT2 inhibitor on metabolic parameters. Despite a
similar glucose-lowering effect in the two groups (Table 2 and
Fig. 2a), distinct patterns of change in metabolic parameters were
observed in the SGLT2 inhibitor group. SGLT2 inhibitor caused a
significant increase in fasting serum BHB, ~3.9-fold from baseline
(Fig. 2b) and a significant decrease in serum uric acid and fasting
serum insulin (Fig. 2c, d, respectively) accompanied by an
increase in fasting serum free fatty acid (FFA) (Fig. 2e), while
sulfonylurea had no significant effects on these measurements.
SGLT2 inhibitor induced significant improvement in insulin
sensitivity (Fig. 2f, g), while sulfonylurea led to increased insulin
secretion (Fig. 2h). SGLT2 inhibitor significantly decreased body
weight, with a mean change of −2.5% (Fig. 2i).
SGLT2 inhibitor suppresses NLRP3 inflammasome activation.
Regarding the primary endpoint of the current study, IL-1β
secretion levels were measured from baseline to end of treatment
in isolated macrophages after exposure to 2 mM ATP or 0.2 mM
palmitate as an NLRP3 trigger, with 0.1 μg/mL LPS priming. In
response to ATP stimulation, IL-1β secretion was significantly
reduced after both SGLT2 inhibitor and sulfonylurea treatment
(3733 ± 360 to 2549 ± 320 pg/mL, P < 0.001; and 3777 ± 485 to
3121 ± 345 pg/mL, P= 0.01, respectively) (Fig. 3a). However,
SGLT2 inhibitor showed a greater reduction in IL-1β secretion
compared with sulfonylurea (time × group interaction P= 0.002),
which remained significant after adjustment for body weight
change (time × group interaction P= 0.02). This tendency was
potentiated under the condition of inflammasome stimulation by
palmitate (time × group interaction P < 0.001, Fig. 3b). To further
evaluate metabolic factors associated with changes in inflamma-
some activity, correlation analyses were conducted. Changes in
fasting serum insulin or BHB levels were significantly correlated
with changes in NLRP3 inflammasome activity (Supplementary
Fig. 1).
In parallel with the IL-1β effect, tumor necrosis factor-α (TNF-
α) secretion was significantly reduced after SGLT2 inhibitor
treatment in response to ATP and palmitate stimulation (262 ± 61
to 145 ± 22 pg/mL, P < 0.001; and 271 ± 54 to 148 ± 26 pg/mL,
P < 0.001, respectively) (Fig. 3c, d). Alternatively, sulfonylurea
treatment had no effect on TNF-α secretion in response to ATP
and palmitate stimulation (210 ± 32 to 204 ± 30 pg/mL, P= 0.41;
and 206 ± 35 to 215 ± 31 pg/mL, P= 0.64, respectively). A
previous study found that TNF-α may cause atherosclerosis
through pro-inflammatory actions on leukocytes, endothelial
cells, and adipocytes14. A number of studies have described the
protective effects of TNF antagonists on vascular diseases15. To
rule out the effect of body weight loss on changes in
inflammasome activity, correlation analyses were conducted. As
a result, there was no significant correlation between changes in
body weight and changes in IL-1β or TNF-α release (Supple-
mentary Fig. 2).
Next, we measured the mRNA levels of IL1B, TNFA, and
NLRP3 in unstimulated macrophages following 30-day treatment
with sulfonylurea or SGLT2 inhibitor. The transcripts encoding
IL-1β were significantly decreased following SGLT2 inhibitor
treatment (Fig. 3e). Transcript levels of TNFA and NLRP3 tended
to decrease after SGLT2 inhibitor treatment, but not statistically
significant (Fig. 3f, g). SGLT2 inhibitor significantly decreased the
LPS- and ATP-induced processing of the biologically active form
of IL-1β in cell lysates (Fig. 3h). RNA sequencing with gene
ontology (GO) enrichment analysis identified two clusters of
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upregulated and downregulated genes in SGLT2 inhibitor group
compared with sulfonylurea group. The downregulated genes
were highly enriched for immune-related receptor signaling
pathway, activation of immune response, and regulation of
immune system process, whereas the upregulated cluster was
enriched for genes involved in cellular components such as
vesicles and extracellular region (Supplementary Fig. 3).
Regarding serum IL-1β and IL-18 levels, despite a tendency to
decrease after SGLT2 inhibitor treatment, there were no
significant changes in those concentrations (Supplementary
Table 2). This may be attributable to the following factors: First,
serum IL-1β levels are often undetectable even in diseases with
clear evidence of increased IL-1 activity5,16–18. IL-1β exerts its
effect in an autocrine/paracrine fashion and, consequently, the
detected levels of IL-1β in the serum may be very low19; in our
study, 37 out of 61 participants had serum IL-1β levels below the
detection limits of the assay used. Second, extensive use of aspirin
or statin in both sulfonylurea and SGLT2 inhibitor groups might
attenuate changes in serum pro-inflammatory cytokines20.
Finally, as activation of the NLRP3 inflammasome requires two
independent steps: priming and triggering21, IL-1β signaling in
the immune cells of vessel tissues or of atherosclerotic lesions
enriched for various endogenous danger signals, rather than
circulating IL-1β levels, might be a major determinant of
atheroma formation or heart failure5,22,23. In the present study,
we identified that treatment with an SGLT2 inhibitor can reduce
the activation of NLRP3 inflammasome in human macrophages
after stimulation with LPS and ATP/palmitate.
Effects of BHB, glucose, and insulin on NLRP3 inflammasome.
Although it has been reported that BHB blocks activation of the
NLRP3 inflammasome-IL-1β process by preventing K+ efflux and
reducing apoptosis-associated speck-like protein containing a
caspase recruitment domain (ASC) oligomerization and speck
formation12, we found that its effective concentration was rather
high compared with the modest increase seen after SGLT2 inhi-
bitor treatment. Therefore, other mediators besides BHB may play
important roles in modulating NLRP3 inflammasome activity in
humans. As SGLT2 inhibitor significantly reduced fasting serum
levels of insulin as well as glucose, we performed ex vivo experi-
ments using human macrophages to investigate whether these
metabolites could affect NLRP3 inflammasome activity.
We confirmed that BHB dose-dependently inhibited IL-1β
secretion from human macrophages stimulated by LPS and ATP
(Fig. 4a). Co-treatment with 2-deoxyglucose (2-DG), a non-
metabolizable glucose analog that blocks glycolysis and has been
used to mimic a condition of glucose starvation24, significantly
decreased IL-1β secretion in a dose-dependent manner (Fig. 4b).
Inversely, a high glucose condition (25 mM) markedly increased
IL-1β production, which was blocked by administration of 2-DG
(Fig. 4c). Regarding the role of insulin on NLRP3 inflammasome,
10 nM insulin significantly elevated IL-1β secretion (Fig. 4d).
Furthermore, co-treatment with insulin attenuated the inhibitory
effect of BHB on NLRP3 inflammasome activation (Fig. 4e).
Discussion
We demonstrate that an SGLT2 inhibitor significantly suppresses
NLRP3 inflammasome activation and subsequent secretion of IL-
1β in human macrophages, via increased serum BHB levels and
decreased serum levels of insulin, among patients with T2D and
CVD, regardless of glycemic control. Furthermore, ex vivo
experiments with human macrophages verify the mediatory roles
of BHB, insulin, and glucose on the modulating activity of the
NLRP3 inflammasome.
NLRP3 inflammasome is involved in the molecular etiology of
atherosclerosis and heart failure2,4,5,7. Mice with constitutively
increased IL-1 signaling because of IL-1 receptor antagonist
deficiency develop a transmural arterial inflammation leading to
lethal aneurysms25. In human atherosclerotic plaques, the
expression of IL-1β appears to correlate with the progression of
atherosclerotic plaques26. In an in vitro study, IL-1β and TNF-α
decreased collagen synthesis and activated collagen degradation
in rat cardiac fibroblasts, suggesting that IL-1β and TNF-α may
contribute to ventricular dilation and heart failure3.
Although there is a paucity of large clinical trial data, a number
of observational, pilot, and preclinical studies suggest a beneficial
role of IL-1 blockade in the pathological processes of CVD.
Experimental studies in atherosclerosis-prone animals have con-
sistently shown that genetic deletion or pharmacological inhibi-
tion of IL-1 signaling reduces the formation and progression of
atherosclerotic plaques5,7. For example, transplantation of bone
marrow cells from NLRP3- or IL1-deficient mice into mice models
of atherosclerosis resulted in significant amelioration of aortic
atherogenesis4. In terms of heart failure, when exposed to
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Fig. 1 Participant flow diagram. Numbers of participants who were initially screened, underwent random allocation, withdrew, and were included in the
final analysis. SGLT2 sodium–glucose cotransporter 2.
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ischemia-reperfusion injury, mice that lack the NLRP3 gene have a
smaller infarct size and better cardiac function than wild-type
mice27. In the recent CANTOS (Canakinumab Anti-inflammatory
Thrombosis Outcomes Study) trial, canakinumab, a monoclonal
antibody against IL-1β, significantly prevented recurrent CV
events among patients with a prior myocardial infarction (MI) and
high levels of pro-inflammatory biomarkers28. This randomized
controlled trial (RCT) implicates that reducing low-grade
inflammation in CVD patients without affecting blood choles-
terol levels can decrease the risk of developing CV events. In
addition, it confirms the clinical importance of the proatherogenic
characteristics of IL-1β in humans.
Previously, subgroup analyses from EMPA-REG OUT-
COME or CANVAS Program did not show a significant
reduction in MI or stroke by SGLT2 inhibitors9,10; however,
these secondary endpoints could not be proven with relatively
small numbers of trial participants. In a recent meta-analysis
of 71 RCTs29 and the large multinational CVD-REAL
2 study30, SGLT2 inhibitors significantly decreased MI and
stroke events, as well as all-cause death and hospitalization for
heart failure, suggesting their anti-atherothrombotic effects.
Our study suggests that SGLT2 inhibitors offer not only
improvements in metabolic profiles but also inhibition of IL-
1β secretion and other pro-inflammatory cytokines, potentially







Age (years) 64.9 ± 8.60 63.9 ± 9.18 0.64
Male sex [n (%)] 22 (68.8) 24 (82.8) 0.20
Body weight (kg) 69.5 ± 11.0 73.0 ± 14.8 0.30
BMI (kg/m2) 26.0 (24.3–27.9) 26.3 (24.3–28.0) 0.98
Currently smoking [n (%)] 3 (9.38) 7 (24.1) 0.17
Systolic blood pressure (mmHg) 129.3 ± 14.0 127.8 ± 15.4 0.71
Diastolic blood pressure (mmHg) 73.6 ± 10.1 76.3 ± 11.3 0.33
Duration of diabetes (years) 7.58 (3.39–14.1) 7.58 (4.00–12.6) 0.83
Cardiovascular disease
History of ACSa [n (%)] 13 (40.6) 16 (55.2) 0.26
History of AMI [n (%)] 9 (28.1) 8 (27.6) 0.96
Multi-vessel CAD [n (%)] 22 (68.8) 23 (79.3) 0.35
PTCA [n (%)] 23 (71.9) 18 (62.1) 0.42
Coronary artery bypass graft [n (%)] 3 (9.38) 3 (10.3) >0.99
Gluco-metabolic indices
HbA1C (%) 7.25 (6.75–8.00) 6.90 (6.45–7.80) 0.25
Glycated albumin (%) 17.4 (15.7–21.0) 17.2 (15.3–19.9) 0.50
Fasting serum glucose (mg/dL) 139.0 (127.8–171.5) 128.0 (123.5–147.0) 0.05
Fasting serum BHB (mM) 0.07 ± 0.07 0.06 ± 0.04 0.21
Uric acid (mg/dL) 4.96 ± 1.43 4.75 ± 1.19 0.54
AST (IU/L) 24.0 (19.3–33.0) 22.0 (19.5–29.0) 0.41
ALT (IU/L) 24.0 (19.0–34.0) 27.0 (18.5–35.0) 0.60
Total cholesterol (mg/dL) 139.0 (118.5–158.0) 133.0 (117.5–147.0) 0.30
Triglyceride (mg/dL) 126.5 (101.3–183.5) 143.0 (104.0–188.0) 0.76
HDL cholesterol (mg/dL) 43.6 ± 10.2 42.0 ± 9.77 0.54
LDL cholesterol (mg/dL) 65.2 (43.2–75.2) 63.4 (47.4–71.2) 0.40
Creatinine (mg/dL) 0.85 (0.73–1.00) 0.84 (0.77–0.92) 0.61
eGFR CKD-EPI (mL/min per 1.73 m2) 86.0 (74.8–94.5) 92.0 (83.0–98.5) 0.08
Insulin secretory/resistant indices
Fasting serum insulin (µU/mL) 9.60 (7.36–16.8) 8.09 (5.31–11.9) 0.08
Fasting serum FFA (μEq/L) 426.5 (351.5–527.0) 412.0 (284.0–517.0) 0.41
HOMA-IR 3.89 (2.32–7.42) 2.72 (1.74–4.40) 0.05
QUICKI 0.32 ± 0.03 0.33 ± 0.03 0.05
HOMA-β (%) 46.2 (29.8–92.4) 48.7 (27.6–55.5) 0.42
Drug use
Antiplatelet/anticoagulant agents [n (%)] 30 (93.8) 27 (93.1) >0.99
Statin [n (%)] 29 (90.6) 27 (93.1) >0.99
Fibrate [n (%)] 3 (9.38) 4 (13.8) 0.70
ACE inhibitor/ARB [n (%)] 20 (62.5) 18 (62.1) 0.97
Diuretics [n (%)] 4 (12.5) 2 (6.90) 0.67
Calcium channel blockers [n (%)] 6 (18.8) 4 (13.8) 0.74
Beta blockers [n (%)] 22 (68.8) 15 (51.7) 0.17
Metformin [n (%)] 31 (96.9) 26 (89.7) 0.34
Mann–Whitney U or two-sample Student’s t test for continuous variables and a Pearson χ2 test for categorical variables; continuous variables are described as mean ± SD for parametric variables and as
median (interquartile range) for non-parametric variables. Source data are provided as a Source Data file.
ACE angiotensin-converting enzyme, ACS acute coronary syndrome, ALT alanine aminotransferase, AMI acute myocardial infarction, ARB angiotensin II receptor blocker, AST aspartate aminotransferase,
BHB β-hydroxybutyrate, BMI body mass index, CAD coronary artery disease, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, FFA free fatty acid,
HbA1C glycated hemoglobin, HDL high-density lipoprotein, HOMA-β homeostatic model assessment of pancreatic β-cell function, HOMA-IR homeostatic model assessment of insulin resistance, LDL low-
density lipoprotein, n number of patients, PTCA percutaneous transluminal coronary angioplasty, QUICKI quantitative insulin sensitivity check index, SD standard deviation, SGLT2 sodium–glucose
cotransporter 2.
aHistory of AMI or unstable angina.
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reducing the development of CVD in high risk patients with
diabetes.
Glycosuria resulting from SGLT2 inhibition subtracts glucose
from blood, and relative hypoinsulinemia reduces tissue glucose
uptake, producing a compensatory increase in lipid oxidation and
a concomitant rise in serum BHB levels8. In a previous in vivo
study, the activity of NLRP3 inflammasome was suppressed in
healthy individuals after 24-h fasting13, which can significantly
increase BHB levels, although this study did not measure serum
levels of BHB in the fasted states. Along with reproducible out-
comes of the inhibitory effect of BHB on NLRP3 inflammasome
in our ex vivo study, we assumed that decreases in serum insulin
level induced by SGLT2 inhibitor might also play a role in NLRP3
inflammasome inhibition. A recent study reported that insulin
reinforced a pro-inflammatory pattern of macrophages via
increased glucose uptake followed by subsequent glucose cata-
bolism and production of reactive oxygen species, which even-
tually secreted IL-1β mediated by NLRP3 inflammasome
activation31. Indeed, sulfonylurea increases insulin secretion, in
turn reducing blood glucose levels. In contrast, SGLT2 inhibitor
decreases blood glucose by renal glucose excretion, in turn
decreasing serum insulin levels. These opposing changes in
insulin levels might differentially regulate NLRP3 inflammasome
in the two groups. In addition, similar to our findings, SGLT2
inhibitors have been shown to reduce serum uric acid levels
through increasing renal clearance of uric acid32, a potent acti-
vator of NLRP3 inflammasome12. Taken together, not only
increased serum BHB, but also decreased serum levels of insulin,
glucose, and uric acid, account for the overall inhibitory effect of
SGLT2 inhibitor on the NLRP3 inflammasome.
A limitation of this study is that we did not assess whether the
changes in inflammasome activity by SGLT2 inhibitor could be
linked to the improvement in CV outcomes due to a relatively
short-term trial design. However, both experimental evidence
using NLRP3/IL1 knockout mice and the recent large-scale
CANTOS trial indicate that therapeutic interference with IL-1β
production or function can improve long-term CV outcomes4,7,28.
The present study is a proof-of-concept RCT aimed to elucidate
the glucose-independent mechanism of SGLT2 inhibitors
regarding CV protection. Preventive benefits were observed after
3 months of treatment in the EMPA-REG OUTCOME study; the
present study demonstrates that only 1 month of SGLT2 inhibitor
treatment can suppress inflammasome activation in individuals
with T2D at high risk of CVD. Besides our findings, it is important
to bear in mind that there may be multiplicity of other pathways
or mechanisms which can be directly or indirectly involved in the
protection of CVD by SGLT2 inhibitors. Nevertheless, the present
study provides distinct evidence that SGLT2 inhibitor suppresses
NLRP3 inflammasome activation in patients with T2D at high risk
of CVD.
In conclusion, the present study shows that SGLT2 inhibitor
treatment in patients with T2D at high risk of CVD attenuates
NLRP3 inflammasome activation and secretion of IL-1β, which
has a pathogenic effect on both T2D and CVD, in part via
increased serum BHB and decreased serum insulin, glucose, and
uric acid (Fig. 5). Moreover, the effects of BHB and insulin on
NLRP3 inflammasome activation have also been verified ex vivo.
The present data suggest that these mechanisms might help to
explain the cardioprotective effects of SGLT2 inhibitor in
humans.
Methods
Study design. The present prospective, randomized, open, active-controlled, 2-
arm parallel interventional study was carried out at Severance Hospital between
November 2016 and July 2017. This RCT complied with the Declaration of Hel-
sinki, and is registered at clinicaltrials.gov. (NCT02964572). The protocol was
approved by the Institutional Review Board at Severance Hospital (4-2016-0795).
All participants provided their written informed consent.
Patients. Eligible participants were aged 20–79 years with a diagnosis of T2D and
high CV risk, having inadequate blood glucose control with metformin-based oral
hypoglycemic agents (OHAs). High CV risk was defined as the presence of ≥1 of
the following based on previous literatures9,33: (1) history of acute coronary syn-
drome (MI or unstable angina); (2) evidence of multi-vessel coronary artery disease
documented by coronary angiography; (3) evidence of occlusive peripheral artery
disease documented by angiography or ankle brachial index; (4) evidence of carotid
atherosclerosis defined as presence of carotid artery plaques or ≥0.9 mm of peak
carotid intima-media thickness documented by common carotid arterial ultra-
sound examinations34; (5) body mass index (BMI) ≥ 25 kg/m2, with at least two of
the following: history of hypertension, current smoking, or steatohepatitis.
Inadequate blood glucose control was defined as: (1) glycated hemoglobin (HbA1C)
Table 2 Effects of sulfonylurea and SGLT2 inhibitor on metabolic parameters.
Sulfonylurea (n= 32) SGLT2 inhibitor (n= 29) Ptime × group
Baseline Day 30 P Baseline Day 30 P
Body weight (kg) 69.5 ± 11.0 69.1 ± 10.3 0.47 73.0 ± 14.8 71.2 ± 14.1 <0.001 <0.001
Glycated albumin (%) 17.4 (15.7–21.0) 16.9 (14.8–18.9) <0.001 17.2 (15.3–19.9) 16.3 (14.4–18.3) 0.01 0.32†
Fasting serum glucose (mg/dL) 139.0 (127.8–171.5) 131.0 (112.0–165.8) 0.14 128.0 (123.5–147.0) 124.0 (112.5–138.0) 0.13 0.64†
Fasting serum BHB (mM) 0.07 ± 0.07 0.07 ± 0.07 0.60 0.06 ± 0.04 0.20 ± 0.19 <0.001 <0.001
Fasting serum BHB (fold increase) 1 1.29 1 3.91
Uric acid (mg/dL) 4.96 ± 1.43 5.00 ± 1.34 0.94 4.75 ± 1.19 4.39 ± 1.08 0.01 0.08
AST (IU/L) 24.0 (19.3–33.0) 25.0 (20.5–31.5) 0.95 22.0 (19.5–29.0) 23.0 (19.0-27.0) 0.54 0.45†
ALT (IU/L) 24.0 (19.0–34.0) 27.5 (20.3–36.0) 0.94 27.0 (18.5–35.0) 24.0 (17.0–28.5) 0.07 0.06†
Total cholesterol (mg/dL) 139.0 (118.5–158.0) 137.5 (128.0–147.8) 0.48 133.0 (117.5–147.0) 129.0 (115.0–146.0) 0.86 0.61†
Triglyceride (mg/dL) 126.5 (101.3–183.5) 142.5 (99.3–182.3) 0.96 143.0 (104.0–188.0) 113.0 (87.5–180.5) 0.15 0.18†
HDL cholesterol (mg/dL) 43.6 ± 10.2 42.6 ± 8.46 0.36 42.0 ± 9.77 43.7 ± 10.7 0.27 0.15
LDL cholesterol (mg/dL) 65.2 (43.2–75.2) 67.2 (53.5–82.0) 0.11 63.4 (47.4–71.2) 57.2 (47.6–73.3) 0.96 0.76†
Creatinine (mg/dL) 0.85 (0.73–1.00) 0.86 (0.73–1.00) 0.41 0.84 (0.77–0.92) 0.84 (0.77–0.95) 0.14 0.54†
eGFR CKD-EPI (mL/min per 1.73 m2) 86.0 (74.8–94.5) 85.5 (74.3–93.5) 0.39 92.0 (83.0–98.5) 91.0 (78.5–98.0) 0.16 0.59†
Fasting serum insulin (µU/mL) 9.60 (7.36–16.8) 10.7 (6.15–19.6) 0.34 8.09 (5.31–11.9) 6.09 (4.50–8.94) <0.001 0.002†
Fasting serum FFA (μEq/L) 426.5 (351.5–527.0) 416.0 (333.5–536.8) 0.60 412.0 (284.0–517.0) 523.0 (417.5–637.5) <0.001 0.01†
HOMA-IR 3.89 (2.32–7.42) 3.46 (2.06–7.05) 0.98 2.72 (1.74–4.40) 1.92 (1.32–2.91) <0.001 0.01†
QUICKI 0.32 ± 0.03 0.32 ± 0.03 0.85 0.33 ± 0.03 0.35 ± 0.03 <0.001 0.01
HOMA-β (%) 46.2 (29.8–92.4) 70.7 (25.8–112.3) 0.02 48.7 (27.6–55.5) 38.6 (26.5–52.4) 0.09 0.004†
Spot urine UGCR (mg/mg)* 0.07 (0.05–0.26) 0.07 (0.05–0.16) 0.22 0.11 (0.06–0.38) 43.3 (33.1–55.1) <0.001 <0.001†
Bold values indicate statistical significance. *Urinary glucose levels are expressed as UGCR to minimize the influence of variations of kidney function using the following formula: spot urine UGCR (mg/
mg) = [spot urine glucose (mg/dL) / spot urine creatinine (mg/dL)]. Statistical significance for the time × group interaction was evaluated by using repeat-measures analysis of variance (ANOVA)
(†Non-normally distributed variables were log transformed for analysis and back transformed for presentation). Two-sided paired t test or Wilcoxon signed rank test; continuous variables are described
as mean ± SD for parametric variables and as median (interquartile range) for non-parametric variables. Source data are provided as a Source Data file.
ALT alanine aminotransferase, AST aspartate aminotransferase, BHB β-hydroxybutyrate, CKD-EPI Chronic Kidney Disease Epidemiology Collaboration, eGFR estimated glomerular filtration rate, FFA free
fatty acid, HDL high-density lipoprotein, HOMA-IR homeostatic model assessment of insulin resistance, LDL low-density lipoprotein, QUICKI quantitative insulin sensitivity check index, SD standard
deviation, SGLT2 sodium–glucose cotransporter 2, UGCR urinary glucose-to-creatinine ratio.
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≥6.5% checked within the last 3 months; (2) fasting serum glucose >120 mg/dL; or
(3) random serum glucose >180 mg/dL. Key exclusion criteria included: (1) type 1
diabetes; (2) pregnant women; (3) estimated glomerular filtration rate ≤45 mL/min
per 1.73 m2; (4) active cancer; (5) any uncontrolled endocrine disorder; or (6)
active infection. The inclusion criteria were amended from HbA1c ≥ 7% or fasting
serum glucose ≥130 mg/dL to HbA1c ≥ 6.5% or fasting serum glucose >120 mg/dL
early in the course of the study.
Randomization. Participants who met the eligibility criteria were randomly assigned
in a 1:1 ratio to receive empagliflozin or glimepiride once daily, stratifying for baseline
HbA1C (<8% or ≥8%) and BMI (<25 kg/m2 or ≥25 kg/m2) using a computer-
generated permuted block randomization (a block size of four). Each participant
received 10mg or 25mg once-daily dose of empagliflozin, or glimepiride at an
individualized dose according to risk of hypoglycemia and status of glycemic control
(average dose was 2mg). In participants who were previously treated with
metformin-based OHAs, non-metformin OHAs were substituted with a study drug
(either empagliflozin or glimepiride), or a study drug was added to OHAs. In drug
naive participants, monotherapy with a study drug was initiated. OHA administra-
tion was maintained throughout the 30-day study period. A schematic illustrating the
temporal organization of the study is shown in Supplementary Fig. 4.
Outcome measures. The primary endpoint was the group difference in the levels
of IL-1β secreted from macrophages, before and after the administration of
SGLT2 inhibitor or sulfonylurea. The secondary endpoints were the group dif-
ferences in the levels of TNF-α secreted from macrophages, serum levels of BHB,
insulin secretory/resistant indices, and other biochemical profiles (glycated
albumin, glucose, uric acid, liver enzymes, lipid profiles, creatinine, and FFA),
urinary glucose excretion, and body weight, before and after the administration
of SGLT2 inhibitor or sulfonylurea. Quantitative PCR (qPCR) and immunoblot
analyses for NLRP3, IL-1β, and TNF-α were performed and compared between
two treatment groups. For post-hoc analyses, RNA sequencing and GO
enrichment analyses for differentially expressed genes between two groups were
performed using PBMCs before and after treatment. In addition, changes in
serum IL-1β and IL-18 levels from baseline to end of treatment were analyzed.
Clinical and laboratory measurements. A complete physical examination was
conducted and current medications were recorded for all participants. For
laboratory parameters, after overnight fasting, serum BHB was determined by an
enzymatic assay using a commercial reagent from Nittobo Medical Co., Ltd
(Tokyo, Japan) and the Hitachi 7600 analyzer. Serum glucose, glycated albumin,
uric acid, FFA, lipid profiles, and creatinine were measured using a Hitachi 7600
automated chemistry analyzer (Hitachi High-Technologies Corporation, Tokyo,
Japan). Fasting serum insulin was measured by electrochemiluminescence immu-
noassay using a Cobas e601 analyzer (Roche Diagnostics, GmbH, Germany). In
addition, spot urine glucose and creatinine were measured on an AU680 chemistry
system (Beckman Coulter, Inc., Brea, CA, USA) immediately prior to study
initiation and at end of treatment. Baseline HbA1C was measured by immunoassay
using an Integra 800 CTS (Roche Diagnostics). Pancreatic beta cell function and
insulin sensitivity were assessed using the following indices35: homeostatic model
assessment of pancreatic β-cell function (HOMA-β)= [(fasting serum insulin [µU/
mL] × 20)/(fasting serum glucose [mmol/L] – 3.5)]; homeostatic model assessment
of insulin resistance (HOMA-IR)= [(fasting serum insulin [µU/mL] × fasting
serum glucose [mmol/L])/22.5]; and quantitative insulin sensitivity check index
(QUICKI)= [1/(log(fasting serum glucose [mg/dL])+ log(fasting serum insulin
[µU/mL]))]36. The estimated glomerular filtration rate was derived from the
Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI)37. Serum IL-1β
and IL-18 were measured with ELISA using human Quantikine HS ELISA kits
(R&D Systems, MN, USA). The assay sensitivities (the minimum detectable levels)
for IL-1β and IL-18 were 0.033 pg/mL and 1.25 pg/mL, respectively, determined by
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Fig. 2 Effects of SGLT2 inhibitor and sulfonylurea on metabolic parameters. a–i Changes in metabolic parameters from baseline to end of treatment
(sulfonylurea group: n= 32, SGLT2 inhibitor group: n= 29). †Statistical significance for the time × group interaction evaluated by repeat-measures analysis
of variance (ANOVA) (Non-normally distributed variables were log transformed for analysis and back transformed for presentation). Data are represented
as mean ± SEM or median (interquartile range). Two-sided paired t test or Wilcoxon signed rank test; *P < 0.05, **P < 0.01, and ***P < 0.001 versus
baseline. BHB β-hydroxybutyrate, FFA free fatty acid, HOMA-IR homeostatic model assessment of insulin resistance, QUICKI quantitative insulin sensitivity
check index, SEM standard error of the mean, SGLT2 sodium–glucose cotransporter 2. Source data are provided as a Source Data file.
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Fig. 3 Effects of SGLT2 inhibitor and sulfonylurea on secretion of IL-1β and TNF-α from macrophages. ELISA assay measurement of IL-1β secretion from
macrophages exposed to 2mM ATP (a) or 0.2mM palmitate (b) with 0.1 μg/mL LPS priming (sulfonylurea group: n= 32, SGLT2 inhibitor group: n= 29). TNF-
α secretion from macrophages exposed to ATP (c) or palmitate (d). Experiments were repeated twice or three times per sample; bar graphs are drawn using
mean values of those results per sample, whereas the statistical significances are derived from raw data. Data are represented as mean ± SEM. Two-sided
paired t test; *P < 0.05, **P < 0.01, and ***P < 0.001 versus baseline. mRNA levels encoding IL1B (e), TNFA (f), and NLRP3 (g) (n= 6 per group). Two-sided
paired t test or Wilcoxon signed rank test. †Statistical significance for the time × group interaction evaluated by repeat-measures analysis of variance (ANOVA)
(Non-normally distributed variables were log transformed for analysis and back transformed for presentation). h Representative protein levels of molecules
regarding NLRP3 inflammasome activation with or without LPS and ATP stimulation. IL-1β interleukin-1β, NF-κB nuclear factor kappa-light-chain-enhancer of
activated B cells, NLRP3 NLR family, pyrin domain-containing 3, PA palmitate, SEM standard error of the mean, SGLT2 sodium–glucose cotransporter 2, TNF-α
tumor necrosis factor-α. Source data are provided as a Source Data file.
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Isolation and culture of PBMCs. Samples of whole blood were collected into acid
citrate dextrose tubes. PBMCs were isolated from blood by density centrifugation (20
min at 1600 × g (without brakes) at 18–20 °C) using Ficoll Medium (Ficoll-Paque
PLUS, GE Healthcare Life Science, Uppsala, Sweden)13. After removing the top layer
of clear plasma, the PBMC-containing layer was aspirated and the cells were washed
with Dulbecco’s phosphate-buffered saline. Then the cells were re-suspended in RPMI-
1640 supplemented with 1% penicillin, 1% streptomycin, and 10% fetal bovine serum.
To generate human macrophages, cells were incubated at 1 × 106 cells per mL in 24-
well plates in RPMI medium plus 10% fetal bovine serum for 2 h and then incubated
with 20 ng/mL M-CSF for 3 days. After 3 days, the cells were then incubated with fresh
RPMI medium plus 10% fetal bovine serum containing 10 ng/mL M-CSF and the
medium was freshly replaced every 2 days (total 7 days) as previously described13.
Cell stimulation and cytokine assays. Human macrophages were incubated at 1 ×
106 cells per mL in 24-well plates in RPMI medium plus 10% fetal bovine serum with
0.1 μg/mL LPS (Sigma-Aldrich, L6529) for 4 h13. To stimulate the release of IL-1β,
2 mM ATP (Sigma-Aldrich) or 0.2mM palmitate (Sigma-Aldrich, P9767) was added
for the last 1 or 12 h of incubation, respectively. In addition, to evaluate the direct
inhibitory or stimulating effects on NLRP3 inflammasome activation, different con-
centrations of BHB (1, 10, 20, and 30mM), glucose (11.5 and 25mM) and 2-DG as a
calorie restriction mimetic, or insulin (10 nM) were pre-treated for 5 h before adding
LPS and ATP. Supernatants were collected, centrifuged to remove cells and debris, and
stored at −80 °C for later analysis. IL-1β and TNF-α was measured using ELISA
(eBioscience, human 88-7261-88 and human 88-7346-88, respectively). Results were
normalized to cell number, as determined by the CyQuant cell proliferation assay
(Invitrogen). Experiments on the participants were repeated up to three times per
sample. The examiner conducting these experiments remained blinded to the subject’s
clinical status and treatment group assignment throughout the study.
Immunoblot analysis. Total cell lysates with or without stimulation by LPS and
ATP were prepared by lysis of human macrophages with RIPA buffer (cell signaling,











































– + + + + + +
– + + + + + +
– – 1 10 20 30 –





– + + +
– + + +
11.5 11.5 5.75 –





– + + + + +
– + + + + +
– – 10 10 20 20















































11.5 11.5 25 11.5
































– + + +
– + + +
Fig. 4 Effects of BHB, glucose, and insulin on NLRP3 inflammasome activation in human macrophages by ELISA assay. IL-1β secretion when exposed to
vehicle or 2 mM ATP with 0.1 μg/mL LPS priming and increased BHB (1, 10, 20, and 30mM) or 100 nM MCC950, a small-molecule inhibitor of NLRP3
inflammasome (administered for the last 5 hours as a positive control) (a); increased 2-DG (b); increased glucose (11.5 mM vs. 25 mM) (c); 11.5 mM
glucose with/without 10 nM insulin (d); increased BHB (10mM vs. 20mM) with/without 10 nM insulin (e). 5–64 biologically independent samples per
treatment; experiments on each treatment were repeated up to three times per sample. Symbols are data points from independent experiments: n= 137,
90, 58, 64, 28, 24, 5 (a, left to right), 66, 44, 12, 12 (b, left to right), 39, 27, 28, 11 (c, left to right), 48, 33, 21 (d, left to right), 39, 26, 18, 14, 14, 8 (e, left to
right). Data are represented as mean ± SEM. One-way analysis of variance (ANOVA) using Tukey’s test or a two-tailed Student’s t test with the Bonferroni
method for adjusting P values; *P < 0.05, **P < 0.01, and ***P < 0.001. BHB β-hydroxybutyrate, IL-1β interleukin-1β, NLRP3 NLR family, pyrin domain-
containing 3, SEM standard error of the mean, 2-DG 2-deoxyglucose. Source data are provided as a Source Data file.
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2.5mM sodium pyrophosphate) and the protein contents were measured using the
Bradford assay (Bio-Rad, 500-0006). Equivalent amounts of each protein extract were
heat denatured in 5× sample buffer (2% sodium dodecyl sulfate, 62.5mM Tris (pH
6.8), 0.01% bromophenol blue, 1.43 mM mercaptoethanol, and 0.1% glycerol),
separated on 10% polyacrylamide gels, and electrophoretically transferred onto a
polyvinylidenefluoride membrane (Bio-Rad, 1620175). After blocking, membranes
were treated with the following antibodies: anti-p-nuclear factor kappa-light-chain-
enhancer of activated B cells (pNF-κB) (Ser536; Cell Signaling Technology, 3033),
anti-NF-κB (Cell Signaling Technology, 8242), anti-NLRP3 (Santa Cruz Bio-
technology, sc-66846), and anti-IL-1β (Santa Cruz Biotechnology, sc-7884). Immu-
nostaining was performed using chemiluminescent reagents (SuperSignal West Pico
Luminol/Enhancer solution; Thermo Scientific, 34080) and Agfa medical X-ray film
(Mortsel, CURIX 60). Actin protein levels were used as a loading control. Uncropped
scans for western blot analysis are shown in the Source Data file.
Quantitative PCR analysis. Total RNA was isolated from cells with TRIzol
reagent (Invitrogen, 15596–018) following the manufacturer’s instructions, and
then 2 μg total RNA was reverse transcribed into complementary DNA (cDNA)
using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems,
4368814). The cDNA was then amplified in the ABI 7500 sequence detection
system (Applied Biosystems, 4350584) using Power SYBR® Green PCR Master Mix
(Applied Biosystems, 4367659) with the following cycling conditions: 40 cycles of
95 °C for 5 s, 58 °C for 10 s, and 72 °C for 20 s. Target gene expression was nor-
malized to that of glyceraldehyde 3-phosphate dehydrogenase (Gapdh) or Actin,
and quantitative analyses were conducted using the ΔΔcycle threshold method and
StepOne Software version 2.2.2. The primer sets used for qPCR were as follows:
IL1B, forward 5′-GGA CAA GCT GAG GAA GAT GC-3′ and reverse 5′-TCG
TTA TCC CAT GTG TCG AA-3′; TNFA, forward 5′–GTG ACA AGC CTG TAG
CCC AT-3′ and reverse 5′–TAT CTC TCA GCT CCA CGC CA-3′; NLRP3, for-
ward 5′–TCT CAC GCA CCT TTA CCT GC-3′ and reverse 5′–GAT CCC AGC
AGC AGT GTG AC-3′; β–actin, forward 5′-GGA CTT CGA GCA AGA GAT GG-3′
and reverse 5′-AGC ACT GTG TTG GCG TAC AG-3′.
RNA extraction and sequencing. Total RNA was isolated from macrophage
lysates obtained from PBMCs of seven individuals (three from the sulfonylurea
arm, four from the SGLT2 inhibitor arm) before and after treatment using a
Qiagen RNA extraction kit (Qiagen, Valencia, CA, USA). Among seven indivi-
duals, three of three in sulfonylurea group and 3 of 4 in SGLT2 inhibitor group
were treated with metformin before and throughout the study period. Total RNA
quality and quantity was verified on a NanoCrop1000 spectrometer (Thermo
Scientific, Wilmington, DE, USA) and Bioanalyzer 2100 (Agilent technologies, Palo
Alto, CA, USA). RNA sequencing was performed by Macrogen (Seoul, Korea).
Libraries were constructed with the TruSeq RNA Access Library Prep kit (Illumina,
San Diego, CA, USA) and the enriched library was sequenced on an Illumina HiSeq
4000 system. In brief, we started with 1 μg of total RNA, mRNA was first purified
using polyA selection, then chemically fragmented and converted into single-
stranded cDNA using random hexamer priming. Next, the second strand was
generated to create double-stranded cDNA that was ready for the TruSeq library
construction. The short ds-cDNA fragments were then connected with sequencing
adapters, and suitable fragments were separated by agarose gel electrophoresis.
Finally, TruSeq strand-specific mRNA libraries were built by PCR amplification
and quantified using qPCR according to the qPCR Quantification Protocol Guide
and qualified using Bioanalyzer 2100 (Agilent technologies, Palo Alto, CA, USA).
Bioinformatics of RNA-seq data. Sequence reads were mapped against the human
reference genome (NCBI hg19) and analyzed using CLC Genomics Workbench
v.9.0.1 software (CLC Bio, Cambridge, MA, USA). Among a total of 57,773 genes
annotated for expression values based on transcripts, differentially expressed genes
among two groups with statistical significance (P value < 0.05) using the Baggerley’s
test were selected for further analysis. Afterwards, fold change calculated as mean
RPKM values of drug group divided by mean RPKM values of control group (pre-
treatment samples) was utilized for further filtering step with cut-off value of 1.3
for upregulation and 0.77 for downregulation.
GO enrichment analysis. GO enrichment analyses were carried out using database
for annotation, visualization, and integrated discovery (DAVID) (https://david.
ncifcrf.gov/). ENSEMBL gene IDs were used instead of official gene symbols. The
background species was selected as Homo Sapiens for genes with upregulation and
downregulation values. Annotation of genes into GO terms with functional cate-
gories, general annotations, and protein interactions was executed, and biological
process was used for GO category. Afterwards, GO terms with statistical sig-
nificance (Benjamini corrected P value < 0.05) were further visualized using reduce
visualize gene ontology (REViGO) (http://revigo.irb.hr/) using a cut-off of 0.7 for
SimRel similarity scores. Finally, we determined major representative GO terms
and grouped all GO terms into clusters according to treemap view. In addition,
individual GO terms with statistical significance were ranked by degree of statistical
significance according to values of –log(Benjamini corrected P value).
Statistical analysis. All statistical analyses were performed using SPSS version
23.0 for Windows (IBM Corp., Armonk, NY, USA). A normality test was per-
formed for all continuous variables. The characteristics of the study participants
were analyzed according to groups using a Mann–Whitney U or two-sample
Student’s t test for continuous variables and a Pearson χ2 test for categorical
variables. The effects of empagliflozin or glimepiride treatment on secretion of IL-
1β and TNF-α from macrophages and metabolic parameters were assessed by two-
sided paired t-test or Wilcoxon signed rank test. Statistical significance for the





























Fig. 5 Scheme representing the proposed effects of SGLT2 inhibitor on NLRP3 inflammasome activation. BHB β-hydroxybutyrate, FFA free fatty acid, IL-
1β interleukin-1β, NLRP3 NLR family, pyrin domain-containing 3, SGLT2 sodium–glucose cotransporter 2.
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variance (ANOVA). Non-normally distributed variables were log transformed for
analysis and back transformed for presentation. The Pearson’s correlation coeffi-
cient was used for correlation. One-way ANOVA using Tukey’s test or a two-tailed
Student’s t test with the Bonferroni method for adjusting P values for the number
of comparisons being made were used to examine differences between treatments
in ex vivo experiments. All P values < 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
All data generated or analyzed during this study are included in this published article and
its Supplementary Information file. The source data underlying Tables 1, 2, Figs. 2–4, and
Supplementary Table 2 are provided as a Source Data file. The RNA-seq data are
available at the NCBI GEO database with the accession number GSE134329 [https://
www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE134329].
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